Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
Create a narrative
Genus
LSE:GNS Community
1
Narratives
written by author
0
Comments
on narratives written by author
2
Fair Values set
on narratives written by author
Create a narrative
Genus
Popular
Undervalued
Overvalued
Genus
WA
Analyst Price Target
Consensus Narrative from 9 Analysts
Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position
Key Takeaways Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration. Cost-saving and efficiency efforts through the Value Acceleration Programme increase operating profit, with sustainability initiatives driving customer-engaging growth.
View narrative
UK£24.64
FV
28.8% undervalued
intrinsic discount
3.39%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
10 days ago
author updated this narrative
Your Valuation for
GNS
Genus
Your Fair Value
UK£
Current Price
UK£17.54
22.6% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
793m
2015
2018
2021
2024
2025
2027
2030
Revenue UK£793.2m
Earnings UK£9.4m
Advanced
Set as Fair Value